fig6
From: Oxidative stress-mediated inflammation promotes the pathogenesis of amyotrophic lateral sclerosis
Figure 6. Treg numbers and suppressive function of Tresponder proliferation and disease progression in ALS patients in the Open Label Extension (OLE) of the Phase2A study[46]. The dose escalation was 1X, 2X, and 3X q2 months during the 24 weeks of the Open Label Period. Both Treg numbers and suppressive functions were increased (*P < 0.05) for at least the first 2 weeks. During the OLE the progression rate was slowed in the 6 ALS patients that appeared to have responded to the Treg/IL-2 infusions as monitored by the ALS Functional Rating Scale-Revised; whereas 2 ALS patients were unresponsive to the Treg/IL-2 infusions. ALS: Amyotrophic lateral sclerosis.
